Acrivon Therapeutics
ACRV
55 hedge funds and large institutions have $136M invested in Acrivon Therapeutics in 2024 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 25 increasing their positions, 6 reducing their positions, and 5 closing their positions.
317% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 6
140% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 5
25% more capital invested
Capital invested by funds: $109M → $136M (+$27.1M)
15% more funds holding
Funds holding: 48 → 55 (+7)
7.28% more ownership
Funds ownership: 68.7% → 75.99% (+7.3%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$28.4M |
| 2 |
PA
Perceptive Advisors
New York
|
+$19M |
| 3 |
PBA
Paradigm Biocapital Advisors
New York
|
+$5.31M |
| 4 |
SCV
Sands Capital Ventures
Arlington,
Virginia
|
+$3.79M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$3.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$683K |
| 2 |
Renaissance Technologies
New York
|
-$387K |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$175K |
| 4 |
ETC
Exchange Traded Concepts
Oklahoma City,
Oklahoma
|
-$107K |
| 5 |
PCM
Prelude Capital Management
New York
|
-$93K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FDCDDQ
51
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $2.32K | +$3.22K | +400 | New |
|
|
AB
52
Amalgamated Bank
New York
| $2K | – | – | – |
|
|
53
Millennium Management
New York
| – | -$683K | -95,497 | Closed |
|
|
PCM
54
Prelude Capital Management
New York
| – | -$93K | -13,000 | Closed |
|
|
RJA
55
Raymond James & Associates
St Petersburg,
Florida
| – | -$72.9K | -10,200 | Closed |
|
|
AIG
56
American International Group
New York
| – | -$43K | -6,016 | Closed |
|
|
CFM
57
Catalyst Funds Management
Sydney NSW,
Australia
| – | -$7.46K | -1,044 | Closed |
|
58
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$161 | +20 | +667% |
|
ACRV Hedge Fund Activity: Q2 2024 in Review
55 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Acrivon Therapeutics (ACRV) for Q2 2024, worth a combined $136M — up 25% from $109M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ACRV positions and 5 closed out — a net gain of 7 holders — while 25 added to existing stakes and 6 trimmed.
The largest buyer was RA Capital Management, adding an estimated $28.4M. The largest seller was Millennium Management, exiting entirely with an estimated $683K sold.
- 55 institutional investors held Acrivon Therapeutics (ACRV) as of Q2 2024, up from 48 in Q1 2024.
- Funds reported $136M of Acrivon Therapeutics stock for Q2 2024, up 25% quarter-over-quarter.
- 12 funds opened new Acrivon Therapeutics positions in Q2 2024 and 5 closed out, a net change of +7 holders.
- The largest Acrivon Therapeutics buyer in Q2 2024 was RA Capital Management, an estimated $28.4M added.
- The largest Acrivon Therapeutics seller in Q2 2024 was Millennium Management, an estimated $683K sold.
Based on aggregated 13F filings for Q2 2024.